PTO/SB/08B (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

Sheet 1 of 1

COMPLETE IF KNOWN	
Application Number	10/648,593
Filing Date	08/26/2003
First Named Inventor	FEI HUANG
Art Unit	1652
Examiner Name	SWOPE, SHERIDAN
Attorney Docket Number	D0273 NP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	AA	Sixth Annual Conference – Targeted Therapies in the Treatment of Breast Cancer, July 2003; "Development of Src Kinase Inhibitors for the Treatment of Breast Cancer", Arthur P. DeCillis, Group Director, Oncology Clinical Development, Bristol-Myers Squibb Oncology	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant